Screening for Amyloidosis Before Aortic Valve Elective Replacement

Screening for Amyloidosis Before Aortic Valve Elective Replacement - SAVER

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025236

Enrollment

1000

Registered

2021-05-10

Start date

2021-02-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E85.9 I35.0

Interventions

Group 1: severe aortic valve stenosis with or without any additional signs for amyloidosis (clinic, laboratory meassurement, electrocardiogram, echocardiography)

Eligibility

Sex/Gender

All

Age

40 Years to 99 Years

Inclusion criteria

Inclusion criteria: - age =40 years - written informed consent from the patient or of his/her legal guardian - hospitalization for AVR due to degenerative aortic valve stenosis

Exclusion criteria

Exclusion criteria: - hemodynamically unstable patient - severe co-morbidities with an estimated life expectancy of <1 year

Design outcomes

Primary

Measure	Time frame
Number/ proportion of ATTR cases identified by systematic screening	—

Secondary

Measure	Time frame
Characteristics to differentiate patients with and without ATTR	—

Countries

Germany

Contacts

Public ContactIsabel Mattig

Medizinische Klinik m. S. Kardiologie und Angiologie, Campus Charité Mitte, Charité - Universitätsmedizin Berlin

isabel.mattig@charite.de+49 30 450 513 142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026